

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L1 same (initiation or atg)	4

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L2

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History****DATE:** Friday, December 12, 2003 [Printable Copy](#) [Create Case](#)**Set Name**
side by side**Query****Hit Count** **Set Name**
result set*DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR*L2

L1 same (initiation or atg)

4

L2L1

bcl2 same (antisense or ribozyme\$)

65

L1

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Terms	Documents
L5 and atg	124

Database:

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L6

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**
DATE: Friday, December 12, 2003 [Printable Copy](#) [Create Case](#)

Set Name
side by side

Query

Hit Count **Set Name**
result set

DB=USPT,PGPB,JPAB,EPAB,DWPI,TDBD; PLUR=NO; OP=OR

<u>L6</u>	L5 and atg	124	<u>L6</u>
<u>L5</u>	l2 and cancer	290	<u>L5</u>
<u>L4</u>	L2 and cancer\$ and reed	80	<u>L4</u>
<u>L3</u>	L2 and cancer\$ and reed	80	<u>L3</u>
<u>L2</u>	L1 and treat\$	315	<u>L2</u>
<u>L1</u>	bcl2 and (antisense or ribozyme\$)	318	<u>L1</u>

END OF SEARCH HISTORY

File 5: Biosis Previews(R) 1969-2003/Dec W1
 (c) 2003 BIOSIS
 File 6: NTIS 1964-2003/Dec W1
 (c) 2003 NTIS, Intl Cpyrght All Rights Res
 File 8: Ei Compendex(R) 1970-2003/Nov W5
 (c) 2003 Elsevier Eng. Info. Inc.
 File 34: SciSearch(R) Cited Ref Sci 1990-2003/Dec W1
 (c) 2003 Inst for Sci Info
 File 65: Inside Conferences 1993-2003/Dec W1
 (c) 2003 BLDSC all rts. reserv.
 File 71: ELSEVIER BIOBASE 1994-2003/Dec W1
 (c) 2003 Elsevier Science B.V.
 File 73: EMBASE 1974-2003/Dec W1
 (c) 2003 Elsevier Science B.V.
 File 94: JICST-EPlus 1985-2003/Dec W1
 (c) 2003 Japan Science and Tech Corp(JST)
 File 98: General Sci Abs/Full-Text 1984-2003/Oct
 (c) 2003 The HW Wilson Co.
 File 99: Wilson Appl. Sci & Tech Abs 1983-2003/Oct
 (c) 2003 The HW Wilson Co.
 File 135: NewsRx Weekly Reports 1995-2003/Dec W1
 (c) 2003 NewsRx
 File 143: Biol. & Agric. Index 1983-2003/Oct
 (c) 2003 The HW Wilson Co
 File 144: Pascal 1973-2003/Nov W5
 (c) 2003 INIST/CNRS
 File 155: MEDLINE(R) 1966-2003/Nov W4
 (c) format only 2003 The Dialog Corp.
 File 172: EMBASE Alert 2003/Dec W1
 (c) 2003 Elsevier Science B.V.
 File 266: FEDRIP 2003/Oct
 Comp & dist by NTIS, Intl Copyright All Rights Res
 File 315: ChemEng & Biotech Abs 1970-2003/Nov
 (c) 2003 DECHEMA
 File 357: Derwent Biotech Res. _1982-2003/Dec W4
 (c) 2003 Thomson Derwent & ISI
 File 358: Current BioTech Abs 1983-2003/Nov
 (c) 2003 DECHEMA
 File 369: New Scientist 1994-2003/Dec W1
 (c) 2003 Reed Business Information Ltd.
 File 370: Science 1996-1999/Jul W3
 (c) 1999 AAAS
 File 399: CA SEARCH(R) 1967-2003/UD=13924
 (c) 2003 American Chemical Society
 File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info
 File 40: Enviroline(R) 1975-2003/Nov
 File 50: CAB Abstracts 1972-2003/Nov
 (c) 2003 CAB International
 File 103: Energy SciTec 1974-2003/Nov B2
 (c) 2003 Contains copyrighted material
 File 156: ToxFile 1965-2003/Nov W2
 (c) format only 2003 The Dialog Corporation
 File 162: Global Health 1983-2003/Nov
 (c) 2003 CAB International
 File 305: Analytical Abstracts 1980-2003/Nov W3
 (c) 2003 Royal Soc Chemistry
 File 35: Dissertation Abs Online 1861-2003/Oct
 (c) 2003 ProQuest Info&Learning
 File 48: SPORTDiscus 1962-2003/Nov
 (c) 2003 Sport Information Resource Centre
 File 91: MANTIS(TM) 1880-2002/Dec
 2003 (c) Action Potential
 File 149: TGG Health&Wellness DB(SM) 1976-2003/Nov W3
 (c) 2003 The Gale Group
 File 159: Cancerlit 1975-2002/Oct
 (c) format only 2002 Dialog Corporation

File 164:Allied & Complementary Medicine 1984-2003/Dec
(c) 2003 BLHCIS
File 444:New England Journal of Med. 1985-2003/Dec W2
(c) 2003 Mass. Med. Soc.
File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

Set	Items	Description
S1	421	BCL2 (S) (ANTISENSE OR RIBOZYME?)
S2	9	S1 (S) (INITIATION OR ATG)
S3	4	RD (unique items)

>>>KWIC option is not available in file(s): 399

3/3,K/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2003 BIOSIS. All rts. reserv.

0007843694 BIOSIS NO.: 199192089465

MITOCHONDRIAL PROTEIN P26 BCL2 REDUCES GROWTH FACTOR REQUIREMENTS OF NIH3T3 FIBROBLASTS

AUTHOR: REED J C (Reprint); TALWAR H S; CUDDY M; BAFFY G; WILLIAMSON J;
RAPP U R; FISHER G J

AUTHOR ADDRESS: UNIV PENNSYLVANIA SCH MED, DEP PATHOL LAB MED,
PHILADELPHIA, PA 19104, USA**USA

JOURNAL: Experimental Cell Research 195 (2): p277-283 1991

ISSN: 0014-4827

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The *BCL2* (B cell lymphoma/leukemia-2) proto-oncogene encodes a 26-kDa protein that has been localized to the inner mitochondrial membrane and that has been shown to enhance the survival of some types of hematopoietic cells. Here we show that NIH3T3 fibroblasts stably transfected with a *BCL2* expression plasmid exhibit reduced dependence on competence-inducing growth factors (platelet-derived growth factor, PDGF; epidermal growth factor, EGF) for *initiation* of DNA synthesis. The importance of *BCL2* for growth factor-induced proliferation of these cells was further confirmed by the usage of *BCL2* *antisense* oligodeoxynucleotides. The mechanisms by which overexpression of p26 *BCL2* contributes to fibroblast proliferation are unknown, but do not involved alterations in: (a) the production of inositol triphosphates (IP3), (b) PDGF-induced transient elevations in...

3/3,K/2 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2003 The Dialog Corp. All rts. reserv.

09744299 21546324 PMID: 11690551

Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.

Uchida T; Gao J P; Wang C; Satoh T; Itoh I; Muramoto M; Hyodo T; Irie A; Akahoshi T; Jiang S X; Kameya T; Baba S

Department of Urology, Kitasato University School of Medicine, Sagami-hara, Kanagawa, Japan. tuchida@med.kitasato-u.ac.jp

Molecular urology (United States) Summer 2001, 5 (2) p71-8, ISSN 1091-5362 Journal Code: 9709255

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... Programmed cell death is a genetically regulated pathway that is altered in many cancers. This process is, in part, regulated by the bcl-2 oncogene. *Antisense* oligodeoxynucleotides (ODNs) targeted to specific

* oncogenes have been used with some therapeutic success in animal models of leukemia and melanoma cells and human Hodgkin's lymphoma. We evaluated the effects of *antisense* ODNs targeted to the bcl-2 oncogene on the proliferation of human renal-cell carcinoma (RCC) cells in vitro and on the growth of human...

... and OS-RC-2) was analyzed by reverse transcriptase-polymerase chain reaction. The effects of phosphorothioated ODNs containing human bcl-2 sense and bcl-2 *antisense* sequences that were transfected with Lipofectin on the proliferation and viability of cultures of established human RCC cell lines were determined by MTS assay. The expression of Bcl-2 protein in ACHN tumor cells following *antisense* bcl-2 (AS2) ODN treatment was evaluated by Western blot analysis, and the extent of apoptosis in these cells was determined by fluorescence-activated cell...

... measuring differences in tumor weight in treated and control mice. RESULTS: Expression of bcl-2 mRNA was detected in all five RCC lines. Treatment with *antisense* bcl-2 ODNs inhibited the growth of all tested RCC cells and decreased Bcl-2 protein expression in ACHN cells. The AS2 *antisense* ODN complementary to the coding region of bcl-2 mRNA showed a superior antiproliferative effect compared with AS1 ODN complementary to the translation *initiation* region. Inhibition by *antisense* bcl-2 ODNs of ACHN cells was dose dependent. The FACS analysis revealed that growth inhibition was associated with the induction of programmed cell death. In vivo, AS2 ODN antitumor activity was noted in locally injected groups. CONCLUSIONS: Treatment of human RCC with *antisense* ODNs targeted to bcl-2 inhibits growth and is associated with the induction of programmed cell death. These results suggest therapeutic use of *antisense* *bcl2* in the treatment of RCC.

3/3,K/3 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2003 The Dialog Corp. All rts. reserv.

08050030 94115767 PMID: 1342969

Analysis of BCL2 and MYC expression in non-Hodgkin's lymphomas by in situ hybridization: correlation with chromosome translocations.

Murty V V; Ladanyi M; Houldsworth J; Mikraki V; Chaganti R S

Laboratory of Cancer Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Diagnostic molecular pathology - the American journal of surgical pathology, part B (UNITED STATES) Dec 1992, 1 (4) p221-8, ISSN 1052-9551 Journal Code: 9204924

Contract/Grant No.: CA-20194; CA; NCI; CA-34775; CA; NCI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

We have used an in situ hybridization method for analysis of expression of *BCL2* and MYC on cytospun preparations of normal and malignant lymphoid cell lines and tissue sections of normal and malignant lymph nodes. The probes comprised 50-mer *antisense* oligonucleotides starting at the *ATG* codons of exon 3 of *BCL2* and exon 2 of MYC. We studied the expression of these two genes in frozen tissue sections of biopsy specimens derived from normal and hyperplastic...

... 18)(q32;q21) and t(8;14)(q24;q32) translocations, and T-cell lymphomas with clonal chromosome abnormalities. While all proliferating cells expressed both genes, *BCL2* expression was increased two- to threefold in follicular lymphomas with t(14;18) and MYC expression was increased two- to four-fold in high-grade...

3/3,K/4 (Item 1 from file: 149)

DIALOG(R) File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

02075412 SUPPLIER NUMBER: 85675410 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that (beta)-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

Lupi, Roberto; Dotta, Francesco; Marselli, Lorella; Del Guerra, Silvia; Masini, Matilde; Santangelo, Carmela; Patane, Giovanni; Boggi, Ugo; Piro, Salvatore; Anello, Marcello; Bergamini, Ettore; Mosca, Franco; Di Mario, Umberto; Del Prato, Stefano; Marchetti, Piero
Diabetes, 51, 5, 1437(6)

May,

2002

PUBLICATION FORMAT: Magazine/Journal; Refereed ISSN: 0012-1797

LANGUAGE: English RECORD TYPE: Fulltext TARGET AUDIENCE: Professional

WORD COUNT: 5891 LINE COUNT: 00503

... Cl.sub.2). The specific primer for human iNOS amplified a 461-bp product (sense: 5'-TCC GAG GCA AAC AGC ACA TTC A-3'; *antisense*: 5'-GGG TTG GGG GTG TGG TGA TGT-3'). The human *Bcl2* primer pair (5'-ACA ACA TCG CCC TGT GGA TGA C-3' and 5'-ATA GCT GAT TCG ACG TTT TGC C-3') and human...

...14). Expression of (beta)-actin as RNA control was analyzed using the following primers, generating a 354-bp product (5'-ACC AAC TGG GAG GAG *ATG* GAG-3' and 5'-CGT GAG GAT CTT CAT GAG GTA AGT C-3'). Multiple exons spanning primers were used to avoid the detection of...

?